{"id":54280,"date":"2023-02-27T19:03:16","date_gmt":"2023-02-27T18:03:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/"},"modified":"2023-02-27T19:03:16","modified_gmt":"2023-02-27T18:03:16","slug":"vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/","title":{"rendered":"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. – VBLT"},"content":{"rendered":"
\n

NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL Therapeutics, (the \u201cCompany\u201d) (NasdaqGM: VBLT) with Notable Labs, Inc. Under the terms of the proposed transaction, Vascular shareholders will end up owning approximately 24% of the combined company, each on a fully-diluted basis and subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.\n<\/p>\n

<\/a><\/p>\n

\nIf you believe that this transaction undervalues the Company and\/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com<\/a>) toll free at any time at 855-768-1857, or visit https:\/\/www.ksfcounsel.com\/cases\/nasdaqgm-vblt\/<\/a> to learn more.\n<\/p>\n

\nTo learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKahn Swick & Foti, LLC
\n
Lewis S. Kahn, Managing Partner, 855-768-1857
\n
lewis.kahn@ksfcounsel.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL Therapeutics, (the \u201cCompany\u201d) (NasdaqGM: VBLT) with Notable Labs, Inc. Under the terms of the proposed transaction, Vascular shareholders will end … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54280","6":"format-standard","7":"category-industry"},"yoast_head":"\nVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL Therapeutics, (the \u201cCompany\u201d) (NasdaqGM: VBLT) with Notable Labs, Inc. Under the terms of the proposed transaction, Vascular shareholders will end ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-27T18:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230227005727\/en\/1115287\/21\/Latest_KSF_M%26A.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. – VBLT\",\"datePublished\":\"2023-02-27T18:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/\"},\"wordCount\":219,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005727\\\/en\\\/1115287\\\/21\\\/Latest_KSF_M%26A.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/\",\"name\":\"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005727\\\/en\\\/1115287\\\/21\\\/Latest_KSF_M%26A.jpg\",\"datePublished\":\"2023-02-27T18:03:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005727\\\/en\\\/1115287\\\/21\\\/Latest_KSF_M%26A.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005727\\\/en\\\/1115287\\\/21\\\/Latest_KSF_M%26A.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. – VBLT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/","og_locale":"en_US","og_type":"article","og_title":"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT - Pharma Trend","og_description":"NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL Therapeutics, (the \u201cCompany\u201d) (NasdaqGM: VBLT) with Notable Labs, Inc. Under the terms of the proposed transaction, Vascular shareholders will end ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-27T18:03:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230227005727\/en\/1115287\/21\/Latest_KSF_M%26A.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. – VBLT","datePublished":"2023-02-27T18:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/"},"wordCount":219,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230227005727\/en\/1115287\/21\/Latest_KSF_M%26A.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/","url":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/","name":"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230227005727\/en\/1115287\/21\/Latest_KSF_M%26A.jpg","datePublished":"2023-02-27T18:03:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230227005727\/en\/1115287\/21\/Latest_KSF_M%26A.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230227005727\/en\/1115287\/21\/Latest_KSF_M%26A.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vascular-biogenics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-vascular-biogenics-ltd-vblt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. – VBLT"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54280"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54280\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}